Innate Pharma SA (IPHA) Actualités

Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 31 décembre 2024

Regulatory News: Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

 Innate Pharma Announces Transformative Strategy to Accelerate Growth

 Strategy anchored on early clinical development of proprietary assets with single-agent potential: Drive innovation with first-in-class ANKET®...

Innate Pharma annonce sa participation a la 43ème J.P. Morgan Healthcare Conference

Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui que son équipe de...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Findings reveal promising early signs that lacutamab may help alleviate some of the most distressing symptoms of cutaneous T cell lymphomas...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

Innate will receive 3m USD upfront plus up to 4.9m USD in conditional tranched investments from The Institute for Follicular Lymphoma Innovation...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma partage les présentations sélectionnées pour le congrès annuel de l’ASH 2024

Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui que des abstracts...